Ebola virus vaccines: Where do we stand?

Clinical Immunology

Volumn 173, Issue , 2016, Pages 44-49

  Pavot, Vincent ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Clinical trials; Ebola virus; Immunology; Vaccines; Viral vectors

Indexed keywords

EBOLA VACCINE; GLYCOPROTEIN; VIRAL PROTEIN;

ADENOVIRIDAE; CHIMPANZEE ADENOVIRUS 3; DRUG RESEARCH; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; VESICULOVIRUS; VIRUS REPLICATION; EBOLAVIRUS; GENETICS; IMMUNOLOGY;

ADENOVIRIDAE; EBOLA VACCINES; EBOLAVIRUS; GLYCOPROTEINS; HUMANS; VESICULOVIRUS; VIRAL PROTEINS;

EID: 84994481822     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2016.10.016     Document Type: Review

References (24)

1. [1] Beeching, N.J., Fenech, M., Houlihan, C.F., Ebola virus disease. BMJ, 349, 2014, g7348.
2. [2] 2014 Ebola Outbreak in West Africa - Case Counts | Ebola Hemorrhagic Fever | CDC, (n.d.). http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/case-counts.html (accessed September 20, 2016).
3. [3] Jones, S.M., Feldmann, H., Ströher, U., Geisbert, J.B., Fernando, L., Grolla, A., Klenk, H.-D., Sullivan, N.J., Volchkov, V.E., Fritz, E.A., Daddario, K.M., Hensley, L.E., Jahrling, P.B., Geisbert, T.W., Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11 (2005), 786–790, 10.1038/nm1258.
4. [4] Stanley, D.A., Honko, A.N., Asiedu, C., Trefry, J.C., Lau-Kilby, A.W., Johnson, J.C., Hensley, L., Ammendola, V., Abbate, A., Grazioli, F., Foulds, K.E., Cheng, C., Wang, L., Donaldson, M.M., Colloca, S., Folgori, A., Roederer, M., Nabel, G.J., Mascola, J., Nicosia, A., Cortese, R., Koup, R.A., Sullivan, N.J., Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat. Med. 20 (2014), 1126–1129, 10.1038/nm.3702.
5. [5] Sullivan, N.J., Martin, J.E., Graham, B.S., Nabel, G.J., Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 7 (2009), 393–400, 10.1038/nrmicro2129.
6. [6] Marzi, A., Robertson, S.J., Haddock, E., Feldmann, F., Hanley, P.W., Scott, D.P., Strong, J.E., Kobinger, G., Best, S.M., Feldmann, H., Ebola vaccine. VSV-EBOV rapidly protects macaques against infection with the 2014e/15 Ebola virus outbreak strain. Science 349 (2015), 739–742, 10.1126/science.aab3920.
7. [7] Zhu, F.-C., Hou, L.-H., Li, J.-X., Wu, S.-P., Liu, P., Zhang, G.-R., Hu, Y.-M., Meng, F.-Y., Xu, J.-J., Tang, R., Zhang, J.-L., Wang, W.-J., Duan, L., Chu, K., Liang, Q., Hu, J.-L., Luo, L., Zhu, T., Wang, J.-Z., Chen, W., Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet. Lond. Engl. 385 (2015), 2272–2279, 10.1016/S0140-6736(15)60553-0.
8. [8] Kibuuka, H., Berkowitz, N.M., Millard, M., Enama, M.E., Tindikahwa, A., Sekiziyivu, A.B., Costner, P., Sitar, S., Glover, D., Hu, Z., Joshi, G., Stanley, D., Kunchai, M., Eller, L.A., Bailer, R.T., Koup, R.A., Nabel, G.J., Mascola, J.R., Sullivan, N.J., Graham, B.S., Roederer, M., Michael, N.L., Robb, M.L., Ledgerwood, J.E., RV 247 Study Team, Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet Lond. Engl. 385 (2015), 1545–1554, 10.1016/S0140-6736(14)62385-0.
9. [9] Regules, J.A., Beigel, J.H., Paolino, K.M., Voell, J., Castellano, A.R., Muñoz, P., Moon, J.E., Ruck, R.C., Bennett, J.W., Twomey, P.S., Gutiérrez, R.L., Remich, S.A., Hack, H.R., Wisniewski, M.L., Josleyn, M.D., Kwilas, S.A., Van Deusen, N., Mbaya, O.T., Zhou, Y., Stanley, D.A., Bliss, R.L., Cebrik, D., Smith, K.S., Shi, M., Ledgerwood, J.E., Graham, B.S., Sullivan, N.J., Jagodzinski, L.L., Peel, S.A., Alimonti, J.B., Hooper, J.W., Silvera, P.M., Martin, B.K., Monath, T.P., Ramsey, W.J., Link, C.J., Lane, H.C., Michael, N.L., Davey, R.T., Thomas, S.J., rVSVΔG-ZEBOV-GP Study Group, A recombinant vesicular stomatitis virus Ebola vaccine — preliminary Report. N. Engl. J. Med., 2015, 10.1056/NEJMoa1414216.
10. [10] Ledgerwood, J.E., Sullivan, N.J., Graham, B.S., Chimpanzee adenovirus vector Ebola vaccine—preliminary report. N. Engl. J. Med., 373, 2014, 776, 10.1056/NEJMc1505499.
11. [11] Ewer, K., Rampling, T., Venkatraman, N., Bowyer, G., Wright, D., Lambe, T., Imoukhuede, E.B., Payne, R., Fehling, S.K., Strecker, T., Biedenkopf, N., Krähling, V., Tully, C.M., Edwards, N.J., Bentley, E.M., Samuel, D., Labbé, G., Jin, J., Gibani, M., Minhinnick, A., Wilkie, M., Poulton, I., Lella, N., Roberts, R., Hartnell, F., Bliss, C., Sierra-Davidson, K., Powlson, J., Berrie, E., Tedder, R., Roman, F., De Ryck, I., Nicosia, A., Sullivan, N.J., Stanley, D.A., Mbaya, O.T., Ledgerwood, J.E., Schwartz, R.M., Siani, L., Colloca, S., Folgori, A., Di Marco, S., Cortese, R., Wright, E., Becker, S., Graham, B.S., Koup, R.A., Levine, M.M., Volkmann, A., Chaplin, P., Pollard, A.J., Draper, S.J., Ballou, W.R., Lawrie, A., Gilbert, S.C., Hill, A.V.S., A monovalent Chimpanzee adenovirus Ebola vaccine boosted with MVA. N. Engl. J. Med. 374 (2016), 1635–1646, 10.1056/NEJMoa1411627.
12. [12] Henao-Restrepo, A.M., Longini, I.M., Egger, M., Dean, N.E., Edmunds, W.J., Camacho, A., Carroll, M.W., Doumbia, M., Draguez, B., Duraffour, S., Enwere, G., Grais, R., Gunther, S., Hossmann, S., Kondé, M.K., Kone, S., Kuisma, E., Levine, M.M., Mandal, S., Norheim, G., Riveros, X., Soumah, A., Trelle, S., Vicari, A.S., Watson, C.H., Kéïta, S., Kieny, M.P., Røttingen, J.-A., Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet Lond. Engl. 386 (2015), 857–866, 10.1016/S0140-6736(15)61117-5.
13. [13] Lee, J.E., Saphire, E.O., Ebolavirus glycoprotein structure and mechanism of entry. Futur. Virol. 4 (2009), 621–635, 10.2217/fvl.09.56.
14. [14] Agnandji, S.T., Huttner, A., Zinser, M.E., Njuguna, P., Dahlke, C., Fernandes, J.F., Yerly, S., Dayer, J.-A., Kraehling, V., Kasonta, R., Adegnika, A.A., Altfeld, M., Auderset, F., Bache, E.B., Biedenkopf, N., Borregaard, S., Brosnahan, J.S., Burrow, R., Combescure, C., Desmeules, J., Eickmann, M., Fehling, S.K., Finckh, A., Goncalves, A.R., Grobusch, M.P., Hooper, J., Jambrecina, A., Kabwende, A.L., Kaya, G., Kimani, D., Lell, B., Lemaître, B., Lohse, A.W., Massinga-Loembe, M., Matthey, A., Mordmüller, B., Nolting, A., Ogwang, C., Ramharter, M., Schmidt-Chanasit, J., Schmiedel, S., Silvera, P., Stahl, F.R., Staines, H.M., Strecker, T., Stubbe, H.C., Tsofa, B., Zaki, S., Fast, P., Moorthy, V., Kaiser, L., Krishna, S., Becker, S., Kieny, M.-P., Bejon, P., Kremsner, P.G., Addo, M.M., Siegrist, C.-A., Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N. Engl. J. Med. 374 (2016), 1647–1660, 10.1056/NEJMoa1502924.
15. [15] Huttner, A., Dayer, J.-A., Yerly, S., Combescure, C., Auderset, F., Desmeules, J., Eickmann, M., Finckh, A., Goncalves, A.R., Hooper, J.W., Kaya, G., Krähling, V., Kwilas, S., Lemaître, B., Matthey, A., Silvera, P., Becker, S., Fast, P.E., Moorthy, V., Kieny, M.P., Kaiser, L., Siegrist, C.-A., VSV-Ebola Consortium, The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect. Dis. 15 (2015), 1156–1166, 10.1016/S1473-3099(15)00154-1.
16. [16] Geisbert, T.W., Feldmann, H., Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J. Infect. Dis. 204:Suppl. 3 (2011), S1075–S1081, 10.1093/infdis/jir349.
17. [17] Gulland, A., Ebola vaccine will be made available for emergency use. BMJ, 532, 2016, i386.
18. [18] De Santis, O., Audran, R., Pothin, E., Warpelin-Decrausaz, L., Vallotton, L., Wuerzner, G., Cochet, C., Estoppey, D., Steiner-Monard, V., Lonchampt, S., Thierry, A.-C., Mayor, C., Bailer, R.T., Mbaya, O.T., Zhou, Y., Ploquin, A., Sullivan, N.J., Graham, B.S., Roman, F., De Ryck, I., Ballou, W.R., Kieny, M.P., Moorthy, V., Spertini, F., Genton, B., Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect. Dis. 16 (2016), 311–320, 10.1016/S1473-3099(15)00486-7.
19. [19] Tapia, M.D., Sow, S.O., Lyke, K.E., Haidara, F.C., Diallo, F., Doumbia, M., Traore, A., Coulibaly, F., Kodio, M., Onwuchekwa, U., Sztein, M.B., Wahid, R., Campbell, J.D., Kieny, M.-P., Moorthy, V., Imoukhuede, E.B., Rampling, T., Roman, F., De Ryck, I., Bellamy, A.R., Dally, L., Mbaya, O.T., Ploquin, A., Zhou, Y., Stanley, D.A., Bailer, R., Koup, R.A., Roederer, M., Ledgerwood, J., Hill, A.V.S., Ballou, W.R., Sullivan, N., Graham, B., Levine, M.M., Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis. 16 (2016), 31–42, 10.1016/S1473-3099(15)00362-X.
20. [20] Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production | Johnson & Johnson, (n.d.). http://www.jnj.com/news/all/Johnson-Johnson-Announces-Major-Commitment-to-Speed-Ebola-Vaccine-Development-and-Significantly-Expand-Production (accessed September 20, 2016).
21. [21] Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2 - Full Text View - ClinicalTrials.gov, (n.d.). https://clinicaltrials.gov/ct2/show/NCT02509494 (accessed September 20, 2016).
22. [22] Sanchez, A., Trappier, S.G., Mahy, B.W., Peters, C.J., Nichol, S.T., The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 3602–3607.
23. [23] Sanchez, A., Ksiazek, T.G., Rollin, P.E., Miranda, M.E., Trappier, S.G., Khan, A.S., Peters, C.J., Nichol, S.T., Detection and molecular characterization of Ebola viruses causing disease in human and nonhuman primates. J. Infect. Dis. 179:Suppl. 1 (1999), S164–S169, 10.1086/514282.
24. [24] Flyak, A.I., Shen, X., Murin, C.D., Turner, H.L., David, J.A., Fusco, M.L., Lampley, R., Kose, N., Ilinykh, P.A., Kuzmina, N., Branchizio, A., King, H., Brown, L., Bryan, C., Davidson, E., Doranz, B.J., Slaughter, J.C., Sapparapu, G., Klages, C., Ksiazek, T.G., Saphire, E.O., Ward, A.B., Bukreyev, A., Crowe, J.E., Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection. Cell 164 (2016), 392–405, 10.1016/j.cell.2015.12.022.